Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

In a recent webinar, experts explored the Most Favored Nation mandate’s implications on drug pricing, patient access, and pharmaceutical innovation.

A new FDA-approved blood test for Alzheimer disease could transform diagnosis and treatment accessibility, according to this conversation with Howard Fillit, MD, and Anthony “Nino” Sireci, MD, MSc.

John Byrnes of Banner|Aetna emphasizes collaboration and data-driven strategies to enhance care quality, access, and affordability in health care.

In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.

Patients with bronchiectasis who are highly symptomatic face an increased risk of future exacerbations, suggesting symptoms should guide prevention strategies.

Participating hospitals in the Prime Vendor Program and the 340B program spent nearly $37.3 billion more on drugs from 2010 to 2021.